Codex DNA Return on Equity

Codex DNA (DNAY) currently reports a ROE of 147.22%. That is above the Healthcare sector average of 22.01%. Use the charts on this page to explore Codex DNA's ROE history and peer comparisons.

Codex DNA's ROE of 147.22% is higher than the Healthcare sector average of 22.01%. That is roughly 568.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Codex DNA's current 147.22% should be judged against Healthcare norms (sector average: 22.01%) and against DNAY's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 147.22%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Codex DNA, and consider following DNAY for alerts when major investors trade the stock.

Codex DNA is classified in the Healthcare sector. On ROE, it currently shows 147.22% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DNAY with unrelated industries.